All In Biotech

Free tool

FAERS Monitor: Bepreve

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022288 or its brand name (Bepreve, Bepotastine Besilate). Reports on generic versions are filed under their own applications.

Reports

644

Serious

361

56% of reports

Hospitalization

174

Death reported

38

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective45
  • headache36
  • nausea33
  • eye irritation32
  • fatigue32
  • pain29
  • diarrhoea28
  • pruritus27
  • treatment failure26
  • dyspnoea25
  • off label use25
  • asthma24
  • arthralgia23
  • malaise23
  • dysgeusia22

Reports by year received

View as table
YearReports
20052
20083
20092
201022
201146
201211
201318
201417
201545
201647
201773
201862
201976
202065
202154
202222
202325
202422
202523
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,515 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye irritationSignal3218.213.0503
treatment failureSignal2610.37.0209
dysgeusiaSignal229.76.4163
asthmaSignal246.94.7117
pruritusSignal272.31.619
headache361.91.414
arthralgia231.81.28
malaise231.71.16
pain291.51.15
dyspnoea251.41.03
diarrhoea281.41.03
nausea331.41.03
fatigue321.31.03
drug ineffective451.10.80
off label use250.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.